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Abstract
Background A healthy diet and optimal lifestyle choices are amongst the most important actions for the prevention of cardio-
metabolic diseases. Despite this, it appears difficult to convince consumers to select more nutritious foods. Furthermore, the 
development and production of healthier foods do not always lead to economic profits for the agro-food sector. Most dietary 
recommendations for the general population represent a “one-size-fits-all approach” which does not necessarily ensure that 
everyone has adequate exposure to health-promoting constituents of foods. Indeed, we now know that individuals show a 
high variability in responses when exposed to specific nutrients, foods, or diets.
Purpose This review aims to highlight our current understanding of inter-individual variability in response to dietary bioac-
tives, based on the integration of findings of the COST Action POSITIVe. We also evaluate opportunities for translation of 
scientific knowledge on inter-individual variability in response to dietary bioactives, once it becomes available, into practi-
cal applications for stakeholders, such as the agro-food industry. The potential impact from such applications will form an 
important impetus for the food industry to develop and market new high quality and healthy foods for specific groups of 
consumers in the future. This may contribute to a decrease in the burden of diet-related chronic diseases.
Key messages 
• Individual differences in ADME (Absorption, Digestion, Metabolism and Excretion) is believed to underpin much 
of the inter-individual variation in responses.
• Recent developments in the area of food metabolome databases and fast improvements in innovative metabotyping 
technologies hold great promise for improved profiling of dietary intake, exposure to individual ingredients, foods 
and dietary patterns, as well as our ability to identify individual responsiveness.
• The food industry needs well-defined population clusters or targets in order to be able to design “personalized 
products”.
• There are indeed excellent industrial opportunities for foods that modulate gut microbiota, and thereby enable 
the delivery of food bioactive metabolites.
• It is currently not clear whether knowledge on individual nutrient needs, based on genetic or metagenomic data, 
would affect long-term dietary and health behaviours.
This article is based upon work from COST Action FA1403 
POSITIVe (Interindividual variation in response to consumption 
of plant food bioactives and determinants involved) supported by 
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• Data to support the development of dietary recommendations may need to be generated by new n-of-1-based study 
designs in the future.
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Inter‑individual variability 
in cardiometabolic response to consumption 
of plant bioactives
The COST Action POSITIVe, a multidisciplinary and cross-
sectorial European network of top-level scientists from more 
than 70 research institutions in 32 countries, members of 
regulatory authorities, and representatives of the food indus-
try, has been instrumental in highlighting the large magni-
tude of individual variation in responses of health biomark-
ers to interventions with plant bioactives [1]. Variability in 
response to intervention is often not accounted for in studies, 
is considered an inconvenient impediment for establishing 
the efficacy of these plant bioactives in population-based 
studies, and is masked by common statistical methods that 
generate an average for the population rather than the indi-
vidual results. Rarely are results reported for all individu-
als in a study to fully describe the extent of variation, but 
when they are, the extent of the variation can be seen to be 
dramatic. For example, total urinary excretion of naringenin 
phase-2 conjugates from a fixed dose of orange juice ranged 
from 1.6 to 59% (37-fold difference) in a study of 129 par-
ticipants [2]. Individual differences in ADME (Absorption, 
Digestion, Metabolism, and Excretion), which includes the 
role of gut microbiota in the metabolism of plant polyphe-
nols and other bioactives, is believed to underpin much of 
the inter-individual variation in responses.
For example, the clustering of urolithin metabotypes has 
helped to understand how inter-individual differences in the 
metabolism of pomegranate ellagitannins can be linked to 
individual differences in responsiveness in cardiovascular 
risk biomarkers [3]. In addition, a recent review that was 
executed as part of the COST Action POSITIVe highlighted 
the large range of factors, including age, BMI, sex, Helico-
bacter pylori infection, blood lipids, drug intake, microbiota 
as well as genetic polymorphisms (e.g., SNPs or single-
nucleotide polymorphisms) that are known (and speculated) 
to influence carotenoid metabolism and exposure [4]. A 
different example shows that variability in the activity of 
polymorphic carriers and post-absorptive phase I and II 
metabolizing enzymes that depend on age, sex, or genotype 
are believed to contribute to the heterogeneity in flavonoid 
ADME. A significant part of the inter-individual variability 
in flavonoid ADME may be attributed to genetic variability 
and the gene–environment interactions, although it is cur-
rently unclear which gene variants and environmental factors 
contribute to responses [5]. Flavonoid ADME are also highly 
dependant on gut microbial metabolism—indeed, some of 
the microbiome-mediated bioconversions result in the pro-
duction of metabolites with enhanced biological activity, 
with one of the best known examples being the conversion 
of soy isoflavones into equol [6]. Lignans constitute a similar 
example, where plant lignans are converted into mammalian 
lignans, enterdiol, and enterolactone by the gut microbiota. 
Main determinants of circulating enterolignans are plant lig-
nan intake, composition, and activity of intestinal microflora, 
antimicrobial use, nutrient intake, BMI, smoking, sex, and 
age [7]. Polyphenols exemplify the complexity of metabolism 
of dietary secondary metabolites: computational analysis 
found that the most characterized 389 polyphenols interacted 
with 5699 unique proteins in an interactome of almost 12,000 
interactions. These interactions mapped to a large number of 
diverse intermediary and regulatory pathways [8].
Inter-individual variation in response to food intake is a 
very recent development in nutrition and health. Knowledge 
of differences in metabolism of most plant food bioactives 
are currently limited to the inter-individual variances in 
plasma or urine concentrations of selected metabolites in 
controlled intervention studies. We only have scattered infor-
mation on how the food matrix may affect the metabolism 
of plant food bioactives. In addition, molecular markers and 
genes of importance in ADME are typically unknown for 
individual compound groups. Extensive literature research 
completed as part of COST Action POSITIVe revealed a 
significant deficit in knowledge about the carriers, enzymes/
isoforms, and gut bacteria involved in absorption and meta-
bolic pathways, making it difficult to identify key molecular 
determinants of ADME variability. Furthermore, a limited 
number of clinical trials have suggested that metabolic or 
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related disease traits of individuals can also influence the 
responsiveness to the consumption of plant sterols and some 
polyphenols [9].
The COST Action POSITIVe group identified a num-
ber of common factors from published human studies that 
appear to affect responsiveness to plant food bioactives. 
Several meta-analyses suggested that the magnitude of the 
responses was generally larger in those who were overweight 
and in subjects at risk of, or currently diagnosed with car-
diovascular disease (CVD). For example, the consumption 
of foods and/or derived products containing flavanols has 
been associated with a significant decrease in body mass 
index (BMI), waist circumference, and total and low-den-
sity lipoprotein (LDL) cholesterol in individuals with a 
BMI ≥ 25.0 kg/m2 [10]. Similarly, in overweight and obese 
populations, the intake of food products containing ellagi-
tannins was associated with a reduction in waist circumfer-
ence, total and LDL cholesterol, triglycerides, glucose, and 
systolic blood pressure (SBP). Similarly, the intake of antho-
cyanin-containing products was associated with a significant 
reduction in both systolic (SBP) and diastolic blood pressure 
(DBP) [11]. These types of results indicate that overweight 
subjects may constitute a target group who would benefit 
most from the intake of these bioactive compounds.
Although numerous systematic reviews and meta-analysis 
have revealed that inter-individual variation in response to 
plant polyphenols is a real issue that warrants further investi-
gation, the underlying concepts and methods of meta-analy-
ses yield limited insights into determinants that drive respon-
siveness to dietary intervention in individuals. Indeed, many 
of the large randomised controlled trials (RTCs) have dem-
onstrated that only ~ 40% of the trial participants respond to 
dietary interventions [12]. Currently, the nutrition and food 
research communities have not conducted the appropriately 
designed interventions, nor do they have the databases that 
would allow data fusion between studies or the grouping 
of individual data. Translating population attributable risks 
to individual risks or benefits has not been accomplished 
except for a few examples [13]. Despite this, a wide range 
of newly launched apps and tools create the impression that 
effective personalised diets can be recommended based on 
limited genetic and phenotypic profiles. These efforts are 
likely premature [14, 15] and could potentially damage the 
scientific reputation of the field and the ability for invest-
ments in the field of personalised and precision nutrition.
What is needed to deliver future impact 
for stakeholders?
To identify the current opportunities and future needs for 
translation of scientific knowledge on inter-individual 
variability in response to dietary bioactives into practical 
applications for stakeholders, we established the main stake-
holders of the research field using a digital Mentimeter Word 
Cloud during the final COST Action POSITIVe meeting in 
September 2019 (Fig. 1). The attendees consisted of a mul-
tidisciplinary and cross-sectorial European network of top-
level scientists (nutritionists, clinicians, geneticists, epide-
miologists, microbiologists, experts in gut microbiome and 
nutrigenomics, bioinformaticians, molecular biologists, and 
food scientists) from more than 70 research institutions in 32 
European countries, members from regulatory agencies and 
representatives of the food industry. The results revealed that 
the food industry was perceived to be one of the most impor-
tant stakeholders in this field, closely followed by academia, 
the nutraceutical industry, consumers, and to a lesser extend 
policy makers and regulatory agencies.
Here, we will discuss available tools, perceived limita-
tions and requirements for each of these stakeholders groups 
to create collective impact on individual and public health 
outcomes in the future (Fig. 2).
Food and nutraceutical industry
The challenge for the food industry is to develop processed 
food products that are shelf-stable, inexpensive, attractive 
for consumers, and that contribute to healthier diets. Ide-
ally, foods would be both desirable and healthy. However, 
consumers often select products that are not based on their 
needs to maintain or improve health. As such, it is important 
for the food industry to better understand consumer pref-
erences, but also how these can be linked to scientifically 
proven health benefits. Developing, marketing, and selling 
these products would have the highest impact on individual 
and public health. However, regulations governing nutrition 
and health claims are mostly focused on health effects of 
individual nutrients in well-defined target groups. The result 
has been an overemphasis on single-functional ingredients 
as the basis for petitioning for health claims. Applications 
Fig. 1  Digital Mentimeter Word Cloud revealing the most important 
stakeholders of the research field of inter-individual variability in 
response to diet
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to regulatory agencies for health claims on foods and drinks 
throughout the European Union (Regulation 1924/2006 
[16]) are expensive and time consuming, and require multi-
ple rigorous scientific studies to substantiate a single claim. 
This is a disadvantage in a competitive market and, there-
fore, may discourage companies from making such invest-
ments. Nevertheless, the development of evidence-based 
marketing messages conveying positive health messages, 
advocating balanced intakes of manufactured and fresh 
foods that also account for nutrient security and sustain-
ability, would contribute to short- and long-term needs of 
industry marketing strategies. Indeed, it is vitally important 
for a food industry that information from health claims can 
actually affect consumer understanding, purchase, and con-
sumption [17]. The requirements for generating evidence 
for healthier foods limit research to larger companies that 
have sufficient revenue for long-term investment in research 
programmes. These often attempt to understand the entire 
chain from molecular mechanisms to evidence from human 
intervention studies. The timeline for such research inten-
sive programmes is often too long to account for the rapidly 
changing consumer “preferences”. Examples are products 
that are gluten-free, organic, alternative protein or packaged 
in sustainable containers.
The challenges involved in the development of healthy 
foods, health claims, and marketing messages become even 
more complicated when considering a market, where the 
demand for personalised products has increased in recent 
years. In order for this new trend to prosper while supporting 
public health, the food industry needs to have well-defined 
population clusters or targets. These targets should extend 
beyond those defined by sex or age, and lead the design of 
“personalised products”. A survey across 84 stakeholders 
from large food companies (40%), the European food and 
drink sector (36%), SMEs (13%), dissemination organi-
sations (6%), public health bodies (4%), and other stake-
holders (food distributors, raw material suppliers, trade 
associations, pharmaceutical companies; 15%) highlighted 
that the majority of stakeholders and end-users believe that 
improved knowledge on the efficacy of plant bioactives can 
help to optimise product development. It is also shared by 
many that improving traditional foods—for example, by 
improving processing methods to increase bioavailability of 
health-promoting compounds from plants—will prove suc-
cessful. The POSITIVe group also concludes that improved 
knowledge on the efficacy of plant bioactives can help to 
optimise product development, especially for specific age 
groups and lifestyle groups. This knowledge should sup-
port the extension of the range of popular products to pro-
vide personalised benefits to the targeted populations. One 
of the largest knowledge gaps in the research field is per-
ceived to be knowledge of metabolism of plant bioactives 
in the human body, presented in databases (Fig. 3). There 
are indeed excellent industrial opportunities for foods that 
modulate gut microbiota, and thereby enable the delivery of 
food bioactive metabolites [18]. Moreover, the microbiota of 
the host appears to be an important determinant of the health 
effects of specific foods, and thus, assessment of subjects’ 
habitual microbiota or biomarkers thereof may be one strat-
egy for tailoring foods for optimal effects across groups of 
individuals [19, 20].
Academia
In general, we lack studies that provide data on both the 
bioavailability of, and biological responsiveness to, plant 
Fig. 2  Schematic overview of 
main stakeholders and collec-
tive key impacts
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Fig. 3  Survey outcomes highlighting key opportunities and require-
ments for the field of dietary plant bioactives amongst 84 key 
stakeholders from the food and drink sector, SMEs, dissemination 
organisations, public health bodies, food distributors, raw material 
suppliers, trade associations, and pharmaceutical companies
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bioactives, especially after standardized intake of plant bio-
actives [21, 22]. Studies are usually too small to allow the 
identification of common factors influencing ADME, or to 
stratify subjects based on responsiveness to identify effects 
and mechanisms in more homogenous groups. Furthermore, 
many studies rely on food intake data which does not neces-
sarily relate to individual exposure to, and bioavailability 
of, plant bioactives. Last but not least, we lack robust and 
database-driven opportunities for data fusion across RCTs 
that allow aggregation of individual data to identify factors 
that explain inter-individual variation in cardiometatobolic 
responses to plant bioactives.
The field would benefit from opportunities, where inter-
individual variability can be investigated in cohort studies 
that facilitate multiple longitudinal samplings and metabolic 
profiling of blood, urine, and the gut microbiome to ascer-
tain cardiometabolic responsiveness. In addition, the field 
would benefit from large RCTs that collect information on 
individual responsiveness to build the robust evidence-base 
to mechanistically understand health benefits and establish 
a cause and effect relationship. Study designs of such RCTs 
should allow for comprehensive baseline profiling and meas-
ure genetic variation, gut microbiota composition, lifestyle, 
and environment [23]. Recent developments in the area of 
metabolomics as well as food metabolome databases, and 
fast improvements in innovative metabotyping technolo-
gies [24–26] hold great promise for our ability to profile 
dietary intake and exposure to individual ingredients, foods 
and dietary patterns, as well as our ability to identify indi-
vidual responsiveness [27]. Combining these data sets would 
improve the ability to establish high probability associations. 
Indeed, metabotyping has been proposed as a stratification 
tool based on ADME capacity, as has been done for equol 
and non-equol producers after intake of soy isoflavones, uro-
lithin metabotypes after the intake of pomegranate ellagitan-
nins [21], or for the urinary excretion of prenyl naringenin 
after hops flavanone intake [28].
Data fusion approaches exploiting studies that have been 
published, or are underway, may allow for the creation of 
larger data sets that would have sufficient statistical power 
to reveal relationships between endogenous factors and car-
diometabolic health outcomes on the individual level. Such 
approaches would also allow the implementation of novel 
computational methods to extend additive genetic risk scores 
to include nonlinear gene–gene, gene–environment, and epi-
genetic interactions that influence responses to plant bioac-
tives and other nutritional variables [29]. However, we found 
that data fusion approaches were inherently difficult because 
of ethical and logistical factors that limit access to data 
and that differences in study designs and outcomes make 
it almost impossible to merge data. Notwithstanding, such 
an approach is of great and common interest to researchers 
working in this area, since it facilitates subgroup analyses 
and gathers evidence for factors driving responsiveness in 
individuals or groups of subjects that share similar charac-
teristics. Indeed, initiatives such as the European Joint Pro-
gramming Initiative (JPI; https ://ec.europ a.eu/progr ammes 
/horiz on202 0/en/h2020 -secti on/joint -progr ammin g-initi 
ative s) a Healthy Diet for a Healthy Life require that data 
collected by funded consortia are made publicly available. 
Similarly, the medical research area has been working on 
the establishment of specific requirements for third-party 
access to anonymized individual data from clinical trial par-
ticipants [30]. This is not a trivial issue, but similar mecha-
nisms to achieve data integration in nutrition research should 
be pursued by the combined efforts of researchers, clinical 
trial units, nutritional journals, and international platforms. 
The sum of these considerations leads to a requirement for 
additional and extensive funding to perform new human 
studies which include the conceptual and methodological 
approaches to analyse variability in response.
Consumers
Recent evidence suggests that a personalised approach 
based on an individual’s diet, phenotype, and environment 
improves healthy eating patterns and choices, at least in the 
short-term and in a research setting [31]. Such personalised 
advice may coincide with an individual’s specific needs and 
habits increasing the feeling of involvement and creating 
a higher awareness. The public appears to be interested in 
the adoption of personalised nutrition services, including 
affordable, simple, and reliable gadgets for self-classification 
and self-monitoring. Direct-to-consumer DNA testing for 
personalised diets has spurred extensive scientific and ethi-
cal debates in the literature about the underlying knowledge 
base for interpreting the results. In addition, consumers 
may have reservations about a service providers’ ability to 
ensure the secure handling of their personal health data [32]. 
A recent study revealed that health apps pose significant 
privacy risks—sharing of private medical user data is rou-
tine, yet far from transparent for users and clinicians [33]. 
A Europe-wide study showed that consumersʼ intention to 
adopt personalised nutrition services depends more on per-
ceived benefit and effectiveness than on perceived privacy 
risk. However, services requiring information of an individ-
ual’s DNA-raised consumers’ perceived privacy risk without 
increasing perceived benefit [34]. Whether knowledge of an 
individual’s nutrient needs based on genetic or metagenomic 
data would affect long-term dietary and health behaviours is 
still unknown. The recent Food4Me study showed that the 
MTHFR genotype did not significantly improve intakes of 
dietary folate [35], and a meta-analysis revealed no signifi-
cant effects of communicating DNA-based risk estimates on 
health behaviours such as smoking, diet, physical activity, 
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alcohol and medication use, or indeed on motivation to 
change behaviour [36].
Most current personalised nutrition approaches provide 
dietary advice based on existing food products. Targeting 
new personalised foods to individuals or groups of individu-
als would have to be produced, marketed, and distributed 
to increasingly small consumer segments. The financial 
viability of products targeted at the group level is uncertain 
[37]. Indeed, personalised foods with controlled ingredi-
ent formulation will be more challenging to produce using 
existing manufacturing processes. Recent developments 
in emerging technologies (such as 3D printing) may pro-
vide new opportunities for the production of personalised 
foods with specific functional properties that meet personal 
requirements and expectations in relation to flavour, colour, 
shape, and texture [38]. This could make personalized nutri-
tion more appealing to consumers and to the food industry 
in the future.
Policy makers and regulatory agencies
Current processes of regulatory agencies are not consistent 
with personalisation of recommendations and dietary advice. 
Dietary guidance is currently based on classical endpoint 
studies using population-based statistics. On the other hand, 
personal and precision nutrition consider individual require-
ments based on individual consumer needs and preferences. 
Data to support the development of recommendations may 
be generated by new n-of-1-based study designs [39]. The 
development of new regulatory pathways beyond the reli-
ance on RCTs with classical endpoints may be necessary, 
possibly including novel approaches assessing individuals’ 
responses that produce replicated results [13]. Developing 
machine-learning regulations will be necessary to ensure 
replicability of data analysis of research and real-world data. 
An interim step would be to focus on nutritional guidelines 
for different population groups defined by data consisting of 
social, lifestyle, and environmental factors.
Another level of complexity for personalisation of recom-
mendations and dietary advice is that guidelines consider 
whole foods and dietary patterns rather than single nutri-
ents or foods. Although it may seem intuitive that responses 
to a single nutrient may produce more replicable results, 
such approaches assume an inflexible metabolic machinery 
inconsistent with first-principles of biological systems that 
flexibly respond to changing environments. In addition, one 
nutrient rarely has a single main mechanism or effect. Omics 
technologies now permit the elucidation of how combina-
tions of nutrients in foods produce specific metabolic read-
outs. Nevertheless, developing health claims of the benefi-
cial effects of whole foods and/or diets is challenging and 
will require new research designs and regulatory guidelines 
for complex mixtures rather than individual nutrients.
Conclusion
Progress in the field of personalised and precision nutri-
tion aims for a better prediction of individual responses 
rather than population-based averages. Our current knowl-
edge was based on statistical approaches and study designs 
that masked inter-individual variability in response to 
dietary bioactives. Here we make a strong case for more 
longitudinal and clinical intervention studies that account 
for inter-individual variability, with the scope of creation 
of databases that would allow data aggregation, stratifica-
tion, and fusion to identify how common factors influence 
ADME and responsiveness to dietary plant bioactives. The 
knowledge coming from such studies and a collaborative 
vision to translate results of these efforts to individual and 
public health will facilitate the establishment of evidence 
based, and hence publicly acceptable, health claims that 
shall support effective marketing strategies to increase 
consumer understanding and consumption of healthier 
foods (Fig. 2).
Acknowledgements This article is based upon work from COST 
Action FA1403 POSITIVe (Interindividual variation in response to 
consumption of plant food bioactives and determinants involved) sup-
ported by COST (European Cooperation in Science and Technology; 
www.cost.eu). BdR is funded by the Scottish Government Rural and 
Environment Science and Analytical Services (RESAS) division.
Author contribution All authors contributed to the design and the edit-
ing of this review.
Funding COST Action FA1403-European Cooperation in Science and 
Technology (www.cost.eu).
Compliance with ethical standards 
Conflict of interest The authors have declared no conflict of interest.
Open Access  This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Manach C, Milenkovic D, Van de Wiele T, Rodriguez-Mateos 
A, de Roos B, Garcia-Conesa MT, Landberg R, Gibney ER, 
Heinonen M, Tomás-Barberán F, Morand C (2017) Addressing 
the inter-individual variation in response to consumption of plant 
food bioactives: Towards a better understanding of their role in 
healthy aging and cardiometabolic risk reduction. Mol Nutr Food 
Res. https ://doi.org/10.1002/mnfr.20160 0557
 2. Brett GM, Hollands W, Needs PW, Teucher B, Dainty JR, Ben-
nett RN, Davis BD, Brodbelt JS, Kroon PA (2009) Absorption, 
S72 European Journal of Nutrition (2019) 58 (Suppl 2):S65–S73
1 3
metabolism and excretion of flavanones from single portions of 
orange fruit and juice and effects of anthropometric variables 
and contraceptive pill use on flavanone excretion. Br J Nutr 
101:664–675
 3. González-Sarrías A, García-Villalba R, Romo-Vaquero M, Ala-
salvar C, Örem A, Zafrilla P, Tomás-Barberán FA, Selma MV, 
Espín JC (2017) Clustering according to urolithin metabotype 
explains the interindividual variability in the improvement of 
cardiovascular risk biomarkers in overweight-obese individuals 
consuming pomegranate: a randomized clinical trial. Mol Nutr 
Food Res 61(5):1600830
 4. Bohn T, Desmarchelier C, Dragsted LO, Nielsen CS, Stahl W, 
Rühl R, Keijer J, Borel P (2017) Host-related factors explaining 
interindividual variability of carotenoid bioavailability and tis-
sue concentrations in humans. Mol Nutr Food Res. https ://doi.
org/10.1002/mnfr.20160 0685
 5. Cassidy A, Minihane AM (2017) The role of metabolism (and the 
microbiome) in defining the clinical efficacy of dietary flavonoids. 
Am J Clin Nutr 105:10–22
 6. Frankenfeld CL (2017) Cardiometabolic risk and gut microbial 
phytoestrogen metabolite phenotypes. Mol Nutr Food Res. https 
://doi.org/10.1002/mnfr.20150 0900
 7. Hålldin E, Eriksen AK, Brunius C, da Silva AB, Bronze M, 
Hanhineva K, Aura AM, Landberg R (2019) Factors explaining 
interpersonal variation in plasma enterolactone concentrations in 
humans. Mol Nutr Food Res. https ://doi.org/10.1002/mnfr.20180 
1159 (epub ahead of print)
 8. Lacroix S, Klicic Badoux J, Scott-Boyer MP, Parolo S, Matone A, 
Priami C, Morine MJ, Kaput J, Moco S (2018) A computationally 
driven analysis of the polyphenol-protein interactome. Sci Rep 
8:2232
 9. Milenkovic D, Morand C, Cassidy A, Konic-Ristic A, Tomás-
Barberán F, Ordovas JM, Kroon P, De Caterina R, Rodriguez-
Mateos A (2017) Interindividual variability in biomarkers of 
cardiometabolic health after consumption of major plant-food 
bioactive compounds and the determinants involved. Adv Nutr 
8:558–570
 10. González-Sarrías A, Combet E, Pinto P, Mena P, Dall’Asta M, 
Garcia-Aloy M, Rodríguez-Mateos A, Gibney ER, Dumont J, 
Massaro M, Sánchez-Meca J, Morand C, García-Conesa MT 
(2017) A systematic review and meta-analysis of the effects of 
flavanol-containing tea, cocoa and apple products on body com-
position and blood lipids: exploring the factors responsible for 
variability in their efficacy. Nutrients 9:746
 11. García-Conesa MT, Chambers K, Combet E, Pinto P, Garcia-
Aloy M, Andrés-Lacueva C, de Pascual-Teresa S, Mena P, Konic 
Ristic A, Hollands WJ, Kroon PA, Rodríguez-Mateos A, Istas 
G, Kontogiorgis CA, Rai DK, Gibney ER, Morand C, Espín JC, 
González-Sarrías A (2018) Meta-analysis of the effects of foods 
and derived products containing ellagitannins and anthocyanins 
on cardiometabolic biomarkers: analysis of factors influencing 
variability of the individual responses. Int J Mol Sci 19:69
 12. de Roos B, Brennan L (2017) Personalised interventions—a pre-
cision approach for the next generation of dietary intervention 
studies. Nutrients 9:E847
 13. Mathias MG, Coelho-Landell CA, Scott-Boyer MP, Lacroix S, 
Morine MJ, Salomão RG, Toffano RBD, Almada MORDV, Cama-
rneiro JM, Hillesheim E, de Barros TT, Camelo-Junior JS, Campos 
Giménez E, Redeuil K, Goyon A, Bertschy E, Lévêques A, Oberson 
JM, Giménez C, Carayol J, Kussmann M, Descombes P, Métai-
ron S, Draper CF, Conus N, Mottaz SC, Corsini GZ, Myoshi SKB, 
Muniz MM, Hernandes LC, Venâncio VP, Antunes LMG, da Silva 
RQ, Laurito TF, Rossi IR, Ricci R, Jorge JR, Fagá ML, Quinho-
neiro DCG, Reche MC, Silva PVS, Falquetti LL, da Cunha THA, 
Deminice TMM, Tambellini TH, de Souza GCA, de Oliveira MM, 
Nogueira-Pileggi V, Matsumoto MT, Priami C, Kaput J, Monteiro JP 
(2018) Clinical and vitamin response to a short-term multi-micronu-
trient intervention in Brazilian children and teens: from population 
data to interindividual responses. Mol Nutr Food Res 62:e1700613
 14. Schaper M, Schicktanz S (2018) Medicine, market and communica-
tion: ethical considerations in regard to persuasive communication in 
direct-to-consumer genetic testing services. BMC Med Ethics 19:56
 15. Badalato L, Kalokairinou L, Borry P (2017) Third party interpreta-
tion of raw genetic data: an ethical exploration. Eur J Hum Genet 
25:1189–1194
 16. Regulation (EC) No 1924/2006 of the european parliament and 
of the council. https ://eur-lex.europ a.eu/legal -conte nt/EN/TXT/
PDF/?uri=CELEX :32006 R1924 &from=en
 17. Hieke S, Kuljanic N, Wills JM, Pravst I, Kaur A, Raats MM, van 
Trijp HC, Verbeke W, Grunert KG (2015) The role of health-related 
claims and health-related symbols in consumer behaviour: Design 
and conceptual framework of the CLYMBOL project and initial 
results. Nutr Bull 40:66–72
 18. Tomás-Barberán FA, Espín JC (2019) Effect of food structure and 
processing on (poly)phenols-gut microbiota interactions and effects 
on human health. Ann Rev Food Sci Technol 10:221–238
 19. Hjorth MF, Blædel T, Bendtsen LQ, Lorenzen JK, Holm JB, Kiiler-
ich P, Roager HM, Kristiansen K, Larsen LH, Astrup A (2019) 
Prevotella-to-Bacteroides ratio predicts body weight and fat loss 
success on 24-week diets varying in macronutrient composition 
and dietary fiber: results from a post hoc analysis. Int J Obes (Lond) 
43:149–157
 20. Kovatcheva-Datchary P, Nilsson A, Akrami R, Lee YS, De Vad-
der F, Arora T, Hallen A, Martens E, Björck I, Bäckhed F (2015) 
Dietary fiber-induced improvement in glucose metabolism is associ-
ated with increased abundance of prevotella. Cell Metab 22:971–982
 21. Selma MV, Romo-Vaquero M, García-Villalba R, González-Sarrías 
A, Tomás-Barberán FA, Espín JC (2016) The human gut microbial 
ecology associated with overweight and obesity determines ellagic 
acid metabolism. Food Funct 7:1769–1774
 22. Bolca S, Possemiers S, Maervoet V, Huybrechts I, Heyerick A, Ver-
varcke S, Depypere H, De Keukeleire D, Bracke M, De Henauw S, 
Verstraete W, Van de Wiele T (2007) Microbial and dietary factors 
associated with the 8-prenylnaringenin producer phenotype: a die-
tary intervention trial with fifty healthy post-menopausal Caucasian 
women. Br J Nutr 98:950–959
 23. Kaput J, van Ommen B, Kremer B, Priami C, Monteiro JP, Morine 
M, Pepping F, Diaz Z, Fenech M, He Y, Albers R, Drevon CA, 
Evelo CT, Hancock RE, IJsselmuiden C, Lumey LH, Minihane AM, 
Muller M, Murgia C, Radonjic M, Sobral B, West KP Jr. (2014) 
Consensus Statement—understanding health and malnutrition 
through a systems approach: the ENOUGH program for early life. 
Gen Nutr 9:378
 24. Ulaszewska MM, Weinert CH, Trimigno A, Portmann R, Andres 
Lacueva C, Badertscher R, Brennan L, Brunius C, Bub A, Capozzi 
F, Cialiè Rosso M, Cordero CE, Daniel H, Durand S, Egert B, Fer-
rario PG, Feskens EJM, Franceschi P, Garcia-Aloy M, Giacomoni 
F, Giesbertz P, González-Domínguez R, Hanhineva K, Hemeryck 
LY, Kopka J, Kulling SE, Llorach R, Manach C, Mattivi F, Migné 
C, Münger LH, Ott B, Picone G, Pimentel G, Pujos-Guillot E, Ric-
cadonna S, Rist MJ, Rombouts C, Rubert J, Skurk T, Sri Harsha 
PSC, Van Meulebroek L, Vanhaecke L, Vázquez-Fresno R, Wishart 
D, Vergères G (2019) Nutrimetabolomics: an integrative action for 
metabolomic analyses in human nutritional studies. Mol Nutr Food 
Res 63:e1800384
 25. Riedl A, Gieger C, Hauner H, Daniel H, Linseisen J (2017) 
Metabotyping and its application in targeted nutrition: an overview. 
Br J Nutr 117:1631–1644
 26. Koistinen VM, da Silva AB, Abrankó L, Low D, Villalba RG, 
Barberán FT, Landberg R, Savolainen O, Alvarez-Acero I, de 
Pascual-Teresa S, Van Poucke C, Almeida C, Petrásková L, 
Valentová K, Durand S, Wiczkowski W, Szawara-Nowak D, 
S73European Journal of Nutrition (2019) 58 (Suppl 2):S65–S73 
1 3
González-Domínguez R, Llorach R, Andrés-Lacueva C, Aura AM, 
Seppänen-Laakso T, Hanhineva K, Manach C, Bronze MR (2018) 
Interlaboratory coverage test on plant food bioactive compounds and 
their metabolites by mass spectrometry-based untargeted metabo-
lomics. Metabolites 8:E46
 27. Garcia-Aloy M, Andres-Lacueva C (2018) Food intake biomarkers 
for increasing the efficiency of dietary pattern assessment through 
the use of metabolomics: unforeseen research requirements for 
addressing current gaps. J Agric Food Chem 66:5–7
 28. Possemiers S, Bolca S, Grootaert C, Heyerick A, Decroos K, 
Dhooge W, De Keukeleire D, Rabot S, Verstraete W, Van de Wiele 
T (2006) The prenylflavonoid isoxanthohumol from hops (Humulus 
lupulus L.) is activated into the potent phytoestrogen 8-prenylnarin-
genin in vitro and in the human intestine. J Nutr 136:1862–1867
 29. Kaput J, Perozzi G, Radonjic M, Virgili F (2017) Propelling the para-
digm shift from reductionism to systems nutrition. Genes Nutr 12:3
 30. Hopkins C, Sydes M, Murray G, Woolfall K, Clarke M, Williamson 
P, Tudur Smith C (2016) UK publicly funded Clinical Trials Units 
supported a controlled access approach to share individual partici-
pant data but highlighted concerns. J Clin Epidemiol 70:17–25
 31. Celis-Morales C, Livingstone KM, Marsaux CF, Macready AL, 
Fallaize R, O’Donovan CB, Woolhead C, Forster H, Walsh MC, 
Navas-Carretero S, San-Cristobal R, Tsirigoti L, Lambrinou CP, 
Mavrogianni C, Moschonis G, Kolossa S, Hallmann J, Godlewska 
M, Surwillo A, Traczyk I, Drevon CA, Bouwman J, van Ommen B, 
Grimaldi K, Parnell LD, Matthews JN, Manios Y, Daniel H, Martinez 
JA, Lovegrove JA, Gibney ER, Brennan L, Saris WH, Gibney M, 
Mathers JC, Food4Me Study (2017) Effect of personalized nutrition 
on health-related behaviour change: evidence from the Food4Me 
European randomized controlled trial. Int J Epidemiol 46:578–588
 32. Stewart-Knox B, Rankin A, Kuznesof S, Poínhos R, Vaz de Almeida 
MD, Fischer A, Frewer LJ (2015) Promoting healthy dietary behav-
iour through personalised nutrition: technology push or technology 
pull? Proc Nutr Soc 74:171–176
 33. Grundy Q, Chiu K, Held F, Continella A, Bero L, Holz R (2019) 
Data sharing practices of medicines related apps and the mobile 
ecosystem: traffic, content, and network analysis. BMJ. https ://doi.
org/10.1136/bmj.l920
 34. Berezowska A, Fischer AR, Ronteltap A, van der Lans IA, van Trijp 
HC (2015) Consumer adoption of personalised nutrition services 
from the perspective of a risk-benefit trade-off. Genes Nutr 10:42
 35. O’Donovan CB, Walsh MC, Gibney MJ, Brennan L, Gibney ER 
(2017) Knowing your genes: does this impact behaviour change? 
Proc Nutr Soc 76:182–191
 36. Hollands GJ, French DP, Griffin SJ, Prevost AT, Sutton S, King S, 
Marteau TM (2016) The impact of communicating genetic risks of 
disease on risk-reducing health behaviour: systematic review with 
meta-analysis. BMJ 352:i1102
 37. de Roos B (2013) Personalised nutrition: ready for practice? Proc 
Nutr Soc 72:48–52
 38. Derossi A, Husain A, Caporizzi R, Severini C (2019) Manufacturing 
personalized food for people uniqueness. An overview from tradi-
tional to emerging technologies. Crit Rev Food Sci Nutr 22:1–19
 39. Schork NJ, Goetz LH (2017) Single-subject studies in transla-
tional nutrition research. Annu Rev Nutr 37:395–422
Affiliations
Baukje de Roos1  · Anna‑Marja Aura2  · Maria Bronze3  · Aedin Cassidy4  · María‑Teresa Garcia Conesa5  · 
Eileen R. Gibney6  · Arno Greyling7  · Jim Kaput8  · Zohar Kerem9  · Nada Knežević10  · Paul Kroon11  · 
Rikard Landberg12 · Claudine Manach13  · Dragan Milenkovic13  · Ana Rodriguez‑Mateos14  · 
Francisco A. Tomás‑Barberán5  · Tom van de Wiele15  · Christine Morand13 
1 The Rowett Institute, University of Aberdeen, Foresterhill, 
Aberdeen AB25 2ZD, UK
2 VTT Technical Research Centre of Finland, PO Box 1000, 
Tietotie 2, Espoo, Finland
3 Instituto de Biologia Experimental e Tecnológica, Apartado 
12, Oeiras, Portugal
4 Department of Nutrition and Preventive Medicine, Norwich 
Medical School, University of East Anglia, Norwich, UK
5 Food and Health Laboratory. Research Group on Quality, 
Safety, and Bioactivity of Plant Foods, CEBAS-CSIC, 
Campus de Espinardo, Murcia, Spain
6 UCD Institute of Food and Health, School of Agriculture 
and Food Science, University College Dublin, Dublin, 
Ireland
7 Unilever Research and Development Vlaardingen, 
Vlaardingen, The Netherlands
8 Vydiant, Sacramento, CA 95816, USA
9 R.H. Smith Faculty of Agriculture, Food and Environment, 
The Hebrew University of Jerusalem, Jerusalem, Israel
10 Podravka d.d, 48000 Koprivnica, Croatia
11 Quadram Institute Bioscience, Norwich Research Park, 
Norwich, UK
12 Division of Food and Nutrition Science, Department 
of Biology and Biological Engineering, Chalmers University 
of Technology, Gothenburg, Sweden
13 INRA, UNH, Unité de Nutrition Humaine, CRNH Auvergne, 
Université Clermont Auvergne, Clermont-Ferrand, France
14 Department of Nutritional Sciences, Faculty of Life Sciences 
and Medicine, School of Life Course Sciences, King’s 
College London, London, UK
15 Faculty of Bioscience Engineering, Center for Microbial 
Ecology and Technology, Ghent University, Ghent, Belgium
